50percent discount on Pfizers new crown vaccine capacity: longer time to expand supply chain than expected

category:Finance
 50percent discount on Pfizers new crown vaccine capacity: longer time to expand supply chain than expected


As early as July, Pfizer and biontech said they would seek conditional sales authorization or some form of regulatory approval by October if the ongoing research was successful. At that time, the production capacity was expected to reach 100 million doses worldwide by the end of 2020, and could exceed 1.3 billion doses by the end of 2021.

However, as a Pfizer spokesman said, the results of the phase III clinical trial did not appear until November. On November 9, Pfizer and biontech announced that the vaccine had been proven to be more than 90% effective; on November 18, the two companies announced a further 95% effective rate.

When the phase III clinical results were released, the two companies said they expected to produce up to 50 million doses of vaccine worldwide by 2020 and 1.3 billion doses by 2021.

Pfizer and baintyco still expect to provide 1.3 billion doses of vaccine in 2021, and the gap of 50 million doses of vaccine this year will be filled as production increases, the Wall Street Journal said.

Fosun Pharmaceutical is the partner of Pfizer / baintyco new crown vaccine in China. In the investor conference call on November 10, Fosun Pharmaceutical Chairman Wu Yifang said: no matter what, there will be a stage of pressure on production capacity.

At the online meeting held by Fosun Pharmaceutical and biontech on November 6, when replying to the questions raised by the surging journalists, byntake also mentioned that the production capacity of new crown vaccine is unprecedented, and the most critical challenge for the production of new crown vaccine is to expand the production capacity.

Ryan Richardson, Chief Strategic Officer of byntac, said that small batches of vaccine used in clinical trials to the final level of 100 million and 1 billion vaccines required very high production requirements. This means that not only the vaccine production process must be better, but also the supply of raw materials should keep pace with it. Therefore, the supply chain should also expand the supply capacity simultaneously. In addition, in order to ensure the expansion of vaccine production in the short term, the supply of core facilities in the production process of new crown vaccine is also very important. Some people in the industry recently told the surging news that the design capacity and actual production capacity of vaccines are two concepts. The production needs to be constructed and the process of amplification is complex. The production capacity in the next few years may be a problem. (this article is from surging news, please download surging news app for more original information) source of this article: surging news editor: Yang Qian_ NF4425

Ryan Richardson, Chief Strategic Officer of byntac, said that small batches of vaccine used in clinical trials to the final level of 100 million and 1 billion vaccines required very high production requirements. This means that not only the vaccine production process must be better, but also the supply of raw materials should keep pace with it. Therefore, the supply chain should also expand the supply capacity simultaneously. In addition, in order to ensure the expansion of vaccine production in the short term, the supply of core facilities in the production process of new crown vaccine is also very important.

Some people in the industry recently told the surging news that the design capacity and actual production capacity of vaccines are two concepts. The production needs to be constructed and the process of amplification is complex. The production capacity in the next few years may be a problem.

(this article is from surging news. For more original information, please download the surging news app)